Hipertensión y Riesgo Vascular

ISSN: 1889-1837

Hipertensión y Riesgo Vascular ha recibido Factor de Impacto (JCR) por primera vez en 2023. Guía para autores - Envío de manuscritos

Indexed in:

Web of Science, Index Medicus/MEDLINE, SCOPUS, IBECS, IME

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2022

0.6

Citescore

CiteScore measures average citations received per document published.

Citescore 2022

1.3

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2022

0.163

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2022

0.26

View more metrics

Hide

Articles in press

Articles in press are accepted, peer reviewed articles that are not yet assigned to volumes/issues, but are citable using DOI. More info

Can catheter-based renal denervation reduce frequency of hospitalization in patients who have resistant hypertension and heart failure with reduced ejection fraction?

B. Güvendi Sengor, C. Yilmaz, M.F. Keten, R. Zehir

Available online 19 April 2024

Miocardiopatía periparto con fallo biventricular más tromboembolismo pulmonar y comunicación interauricular

J.D. Oleas Quezada, J.A. Coyago Iñiguez, E.R. Guerrero Cevallos

Available online 17 April 2024

Valor de la fórmula hematocrito urea y género basal en la evolución a los 17 años de la función renal de ancianos

M. Heras Benito, M.T. Guerrero Díaz, M.A. Rodríguez Gómez, M.J. Fernández-Reyes Luis

Available online 10 April 2024

View all Ahead of print

Current Issue

Issue

Vol. 41. Issue 2.

Pages 73-142 (April - June 2024)

Editorial

Hypertension and Vascular Risk already has an impact factor. Now a new challenge begins

P. Armario, E. Vinyoles, T. Gijon-Conde, C. Arranz, J.M. Galceran

Hipertens Riesgo Vasc. 2024;41:73-4

Is proteinuria an important fact concerning the nephroprotective effect of renin-angiotensin system inhibitors?

J.M. Galceran

Hipertens Riesgo Vasc. 2024;41:75-7

Originales

Estudio de prevalencia, conocimiento y control de la hipertensión arterial en barrios vulnerables de Argentina

W.G. Espeche, M. Marin, C. Romero, N. Renna, S. Vissani, G. Blanco, S.P. Pantalena, D. Cesario, ... M.R. Salazar

Hipertens Riesgo Vasc. 2024;41:78-86

Type 2 diabetes patients requiring empagliflozin in Southeast of Iran: Frequency and guideline adherence (2022–2023)

S.M. Khoshnazar, A. Dehghani, F. Bagheri, S. Pezeshki, G. Yousefzadeh

Hipertens Riesgo Vasc. 2024;41:87-94

View all issue

Free access article

DOCUMENTO DE CONSENSO

Documento de consenso para la determinación e informe del perfil lipídico en laboratorios clínicos españoles

Teresa Arrobas Velilla, Carlos Guijarro, Raquel Campuzano Ruiz, Manuel Rodríguez Piñero, José Francisco Valderrama Marcos, Antonio Pérez Pérez, Manuel Antonio Botana López, Ana Morais López, José Antonio García Donaire, Juan Carlos Obaya, Luis Castilla Guerra, Vicente Pallares Carratalá, Isabel Egocheaga Cabello, Mercedes Salgueira Lazo, María Mar Castellanos Rodrigo, José María Mostaza Prieto, Juan José Gómez Doblas, Antonio Buño Soto

10.1016/j.hipert.2022.12.002

Hipertens Riesgo Vasc. 2023;40:75-84